Paolo Tarantino: Interesting RWA of outcomes with chemotherapy in HR+/HER2- MBC

Paolo Tarantino shared a post by ESMO Open on X, adding:

“Interesting real world analysis of outcomes with chemotherapy in HR+/HER2- MBC. Most used first line chemo: capecitabine. rwPFS for 1L chemo ~7 months, progressively shorter for subsequent lines. Consistent with recent trials in this space. ”

Quoting ESMO Open‘s post:

“Hot off the press: Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States – by Sara Tolaney et al.”

Authors: S.M. Tolaney, K. Punie, L.A. Carey, A.W. Kurian, I. Ntalla, N. Sjekloca, A. Shah, M.K. Rehnquist, M. Stokes, K. Fraeman, W. Verret, K. Jhaveri

Source: Paolo Tarantino/X and ESMO Open/X

More posts featuring Paolo Tarantino on oncodaily.com

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.